장기지속형 항정신병약물의 임상 실제 = The Long-Acting Injectable Antipsychotics in Clinical Practice

다국어 초록 (Multilingual Abstract)

Symptomatic relapse is observed frequently and often associated with social and/or occupational decline that can be difficult to reverse in patients with schizophrenia. Several atypical antipsychotics, including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting injectable antipsychotics (LAIs), and new evidence has been accumulating. LAIs appear to have a significant role in at least a group of schizophrenia patients. Improving the adherence, continuous availability, managing changes in receptor sensitivity, and lowering the requirement of cumulative doses are some of the major advantages of LAIs. Patients with first episode psychosis, dopamine super-sensitivity syndromes, and comorbid substance abuse might particularly benefit. Delaying the initiation of LAI until the establishment of non-adherence is not recommended. The results of clinical trials comparing LAIs with oral antipsychotics (OAPs) are inconsistent because they are influenced considerably by the study design. On the other hand, several barriers to LAIs use in current practice include clinical lack of knowledge, and negative attitudes about LAIs. This article tries to help clinicians better characterize the role of LAIs in the treatment of schizophrenia.

참고문헌 (Reference)

1 Fleischhacker WW, "Treatment of schizophrenia with longacting injectable risperidone : a 12-month open-label trial of the first long-acting second-generation antipsychotic" 64 : 1250-1257, 2003

2 Correll CU, "The use of long-acting injectable antipsychotics in schizophrenia:evaluating the evidence" 77 (77): 1-24, 2016

3 De Hert M, "The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia : a systematic review and meta-analysis of randomized controlled trials with first-and second-generation antipsychotics" 29 : 637-658, 2015

4 Brissos S, "The role of longacting injectable antipsychotics in schizophrenia : a critical appraisal" 4 : 198-219, 2014

5 Haddad PM, "The place of observational studies in assessing the effectiveness of depot antipsychotics" 131 : 260-261, 2011

6 Weiden PJ, "The challenge of offering long-acting antipsychotic therapies : a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia" 76 : 684-690, 2015

7 Naber D, "The CATIE and CUtLASS studies in schizophrenia" 23 : 649-659, 2009

8 Seeman P, "Schizophrenia and the supersensitive synapse" 1 : 233-242, 2011

9 Misawa F, "Safety and tolerability of long-acting injectable versus oral antipsychotics : a metaanalysis of randomized controlled studies comparing the same antipsychotics" 176 : 220-230, 2016

10 Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia" 168 : 498-504, 2015

11 Patel MX, "Psychiatrists’ use, knowledge and attitudesto first-and second-generation antipsychotic long-acting injections : comparisons over 5 years" 24 : 1473-1482, 2010

12 Heres S, "Psychiatrists’ attitudeto antipsychotic depot treatment in patients with first-episode schizophrenia" 26 : 297-301, 2011

13 Patel MX, "Psychiatrists’ attitudes to maintenance medicationfor patients with schizophrenia" 33 : 83-89, 2003

14 Muller P, "Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics" 55 : 149-157, 1979

15 Valenstein M, "Poor antipsychotic adherence among patients with schizophrenia : medication and patient factors" 30 : 255-264, 2004

16 Fu DJ, "Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects : onset of efficacy with recommended initiation regimens" 8 : 101-109, 2014

17 Fu DJ, "Paliperidone palmitate versus oral risperidone and risperidone longacting injection in patients with recently diagnosed schizophrenia : a tolerability and efficacy comparison" 29 : 45-55, 2014

18 Schreiner A, "Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia" 169 : 393-399, 2015

19 Alphs L, "Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics" 9 : 341-350, 2013

20 Zhornitsky S, "Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence : a systematic review" 2012 : 407171-, 2012

21 Morrissette DA, "Optimizing outcomes in schizophrenia : longacting depots and long-term treatment" 17 : 10-21, 2012

22 Hamer J, "One-year treatment continuation in patients switched to paliperidone palmitate : a retrospective study" 75 : 1267-1269, 2014

23 Bushe CJ, "Olanzapine long-acting injection : a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice" 15 : 65-, 2015

24 Kishimoto T, "Longacting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies" 74 : 957-965, 2013

25 Ho BC, "Long-term antipsychotic treatment and brain volumes : a longitudinal study of first episode schizophrenia" 68 : 128-137, 2011

26 Rosenheck RA, "Long-acting risperidone and oral antipsychotics in unstable schizophrenia" 364 : 842-851, 2011

27 Kishimoto T, "Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia : a meta-analysis of randomized trials" 40 : 192-213, 2014

28 Salgueiro M, "Long-acting injectable second-generation antipsychotics in first-episode psychosis : a narrative review" 34 : 51-56, 2019

29 Subotnik KL, "Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial" 72 : 822-829, 2015

30 Kane JM, "Long-acting injectable risperidone : efficacy and safety of the first long acting atypical antipsychotic" 160 : 1125-1132, 2003

31 Rauch AS, "Long-acting injectable formulations of new-generation antipsychotics : a review from a clinical perspective" 27 : 637-652, 2013

32 Malla A, "Long-acting injectable antipsychotics: recommendations for clinicians" 58 (58): 30S-35S, 2013

33 Agid O, "Long-acting injectable antipsychotics in the treatment of schizophrenia : their role in relapse prevention" 11 : 2301-2317, 2010

34 Bartzokis G, "Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia" 140 : 122-128, 2012

35 Hamann J, "How much more effective do depotantipsychotics have to be compared to oral antipsychotics before they are prescribed" 20 : 276-279, 2010

36 Johnson DA, "Historical perspective on antipsychotic long-acting injections" 52 : S7-S12, 2009

37 Carpenter WT Jr, "Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia" 72 : 745-746, 2015

38 Berwaerts J, "Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia : a randomized clinical trial" 72 : 830-839, 2015

39 Savitz AJ, "Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study" 19 : pyw018-, 2016

40 Ishigooka J, "Efficacy and safety of aripiprazole oncemonthly in Asian patients with schizophrenia : a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole" 161 : 421-428, 2015

41 Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia" 353 : 1209-1223, 2005

42 Uchida H, "Dose and dosing frequency of long-acting injectable antipsychotics : a systematic review of PET and SPECT data and clinical implications" 34 : 728-735, 2014

43 Ostuzzi G, "Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies" 183 : 10-21, 2017

44 Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis" 382 : 951-962, 2013

45 Chue P, "Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets" 15 : 111-117, 2005

46 Haijma SV, "Brain volumes in schizophrenia : a meta-analysis in over 18 000 subjects" 39 : 1129-1138, 2013

47 Heres S, "Attitudes of psychiatrists toward antipsychotic depot medication" 67 : 1948-1953, 2006

48 Kane JM, "Aripirazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, doubleblind, placebo-controlled study" 73 : 617-624, 2012

49 Fleischhacker WW, "Aripiprazole oncemonthly for treatment of schizophrenia : double-blind, randomised, non-inferiority study" 205 : 135-144, 2014

50 Aggarwal A, "Aripiprazole lauroxil longacting injectable : the latest addition to second-generation long-acting agents" 10 : 58-63, 2016

51 Bruijnzeel D, "Antipsychotic treatment of schizophrenia : an update" 11 : 3-7, 2014

52 Agid O, "Antipsychotic response in first-episode schizophrenia : efficacy of high doses and switching" 23 : 1017-1022, 2013

53 Patel MX, "Antipsychotic long-acting injections : mind the gap" 52 : S1-S4, 2009

54 Patel MX, "Antipsychotic depot medicationand attitudes of community psychiatric nurses" 12 : 237-244, 2005

55 Gentile S, "Adverse effects associated with second-generation antipsychotic long-acting injection treatment : a comprehensive systematic review" 33 : 1087-1106, 2013

56 Meltzer HY, "A randomized, doubleblind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia" 76 : 1085-1090, 2015

57 Iyer S, "A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part II-physician perspectives" 58 (58): 23S-29S, 2013

58 Iyer S, "A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part I-patient perspectives" 58 (58): 14S-22S, 2013

59 Kimura H, "A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis" 155 : 52-58, 2014

60 Tiihonen J, "A nationwide chohort study of oral and depot antipsychotics after first hospitalization for schizophrenia" 168 : 603-609, 2011

61 Suzuki T, "A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia : a narrative review and critical appraisal" 13 : 253-264, 2016

62 Sreeraj VS, "A critical appraisal of long acting injectable antipsychotics : translating research to clinics" 28 : 57-64, 2017